Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis

被引：0
|
作者：
Bhatia, Neal [1 ]
Vasquez, J. Gabriel [2 ]
Schenkel, Brad
Rozzo, Stephen J. [3 ]
Heim, Jayme [2 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] West Michigan Dermatol, Grandville, MI USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB216 / AB216
页数：1
相关论文
共 50 条
  • [21] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
    James E. Frampton
    [J]. American Journal of Clinical Dermatology, 2019, 20 : 295 - 306
  • [22] Real-world dermatology visit in moderate to severe plaque psoriasis patients treated with biologics or apremilast
    Wu, Jashin J.
    Zhang, Jingchuan
    Zhao, Yang
    Martinez, Diane
    Lopez-Gonzalez, Lorena
    Marchlewicz, Elizabeth H.
    Shrady, George
    Mendelsohn, Alan
    Feldman, Steven
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB80 - AB80
  • [23] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    [J]. JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [24] Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis
    Papadavid, E.
    Rompoti, N.
    Theodoropoulos, K.
    Kokkalis, G.
    Rigopoulos, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (07) : 1173 - 1179
  • [25] Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
    Strober, Bruce
    Ferris, Laura
    Duffin, Kristina Callis
    Janak, Jud C.
    Sima, Adam P.
    Eckmann, Thomas
    Patel, Manish
    Photowala, Huzefa
    Garg, Vishvas
    Armstrong, April
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (01) : 82 - 90
  • [26] Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    April W. Armstrong
    Timothy Fitzgerald
    Robert R. McLean
    Amanda Teeple
    Jonathan P. Uy
    Mobolaji Olurinde
    Katelyn Rowland
    Lin Guo
    Ying Shan
    Kristina Callis Duffin
    [J]. Dermatology and Therapy, 2023, 13 : 629 - 640
  • [27] Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea
    Kim, Byung Soo
    Kim, Dong Hyun
    Shin, Bong Seok
    Lee, Eun-So
    Jo, Seong Jin
    Bang, Chul Hwan
    Yun, Yeojun
    Choe, Yong Beom
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2024, 15
  • [28] Secukinumab demonstrates sustained effectiveness in treating patients with moderate-to-severe plaque psoriasis: real-world evidence from Canada
    Papp, K. A.
    Gooderham, M.
    Delorme, I.
    Lomaga, M.
    Robern, M.
    Hernandez, M. A.
    Taraska, V.
    Ho, V.
    Vieira, A.
    Rihakova, L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 44 - 45
  • [29] One-year real-world effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: analysis from the BADBIR
    Savage, Laura
    Wang, Xiayi
    Johnson, David
    Gillespie, Justin
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 76 - 76
  • [30] Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
    Bucur, Stefana
    Serban, Elena-Daniela
    Ileanu, Bogdan Vasile
    Costache, Raluca Simona
    Nicolescu, Alin Codrut
    Constantin, Traian
    Costache, Daniel Octavian
    Constantin, Maria -Magdalena
    [J]. PSORIASIS-TARGETS AND THERAPY, 2024, 14 : 79 - 86
12345